2. Inhibitory Antibodies
  3. Lirilumab

Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.

For research use only. We do not sell to patients.

CAS No. : 1000676-41-4

Size Price Stock Quantity
1 mg USD 280 In-stock
5 mg USD 700 In-stock
10 mg USD 1100 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Lirilumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].

Isotype

Human IgG4 kappa
Recommend Isotype Controls
Species

Human
In Vivo

Lirilumab (intravenous injection; 15 mg/kg; once) treatment enhances survival rate of mice injected with tumor[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rag1KO-Tg KIR mice injected with tumor cells[2]
Dosage: 15 mg/kg
Administration: intravenous injection; 15 mg/kg; once
Result: Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
Clinical Trial
CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Lirilumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG4 kappa
Biological Activity
  • Immobilized KIR2DL1 Protein, Human (HEK293, His) can bind Lirilumab. The EC50 for this effect is 16.59 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Lirilumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lirilumab1000676-41-4IPH2102IPH 2102IPH-2102Othersantitumor activityLeukemiasquamous cell carcinoma of the head and neckSCCHNInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Lirilumab
Cat. No.:
HY-P99208
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.